Previous 10 | Next 10 |
Natera (NASDAQ: NTRA) has quietly grown its market cap by more than 875% in the past five years, trouncing the 103% gains of the S&P 500 over that time frame. The $10.25 billion med-tech company, which honed its diagnostics craft on non-invasive blood testing to screen for fetal...
peterschreiber.media/iStock via Getty Images CFRA Research has begun the coverage of Guardant Health ([[GH]] +2.0%) with a buy rating as the analysts highlight the underappreciated potential of the company in the market for blood-based cancer tests. Noting Guardant’s LUNAR-2 test as on...
MicroStockHub/E+ via Getty Images Guardant Health (GH) has added two new products to its cancer diagnostic portfolio targeting patients with late-stage and metastatic cancers. The Guardant360 Response test is the first commercially available, blood-only, liquid biopsy test with the ability to...
New Guardant360 Response™ blood test predicts treatment response to immunotherapy and targeted therapy, up to eight weeks earlier than standard-of-care RECIST methods 1-11 New Guardant360 TissueNext™ tissue biopsy test is now available for ordering alon...
Please replace the release dated April 30, 2021, with the following corrected version due to changes in the fifth paragraph. The updated release reads: STUDY SHOWS GUARDANT REVEAL ™ BLOOD-ONLY LIQUID BIOPSY TEST PREDICTS RISK FOR COLORECTAL CANCER RECURRENCE...
Data from 20 abstracts demonstrate value of company’s blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection, and biopharmaceutical drug development Please replace the release dated May 19, 20...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Chris Freeman as the company’s new Chief Commercial Officer for its oncology business, effective June 8, 2021. Chris brings significant experience successfully building an...
Investing in a company operating in an industry tailwind usually leads to significant profits. Guardant Health has been profiting big time from the growing prominence of precision medicine. With a liquid biopsy, Guardant provides physicians and patients crucial information about t...
Results from new patient cohort, the largest to date, consistent with previously reported data Guardant Health, Inc. (Nasdaq: GH) presents new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 4-June 8, 2021, showing that its L...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...